Table 1.

Summary of the Strength of Evidence* Comparing Premixed Insulin Analogues to Other Antidiabetic Agents for Intermediate Outcomes and Adverse Events

	Premixed Insulin Analogues vs. Long- Acting Insulin Analogues	Premixed Insulin Analogues vs. Premixed Human Insulin	Premixed Insulin Analogues vs. Other Insulin Regimens	Premixed Insulin Analogues vs. Noninsulin Antidiabetic Agents
Fasting glucose	Moderate SOE favoring long-acting insulin analogues	Moderate SOE suggesting similar effectiveness	Low SOE; unable to make a conclusion	Moderate SOE favoring premixed insulin analogues
Postprandial glucose	High SOE favoring premixed insulin analogues	High SOE favoring premixed insulin analogues	Low SOE unable to make a conclusion	Moderate SOE favoring premixed insulin analogues
Hemoglobin A1c	High SOE favoring premixed insulin analogues	High SOE suggesting similar effectiveness	Low SOE; unable to make a conclusion	Moderate SOE favoring premixed insulin analogues
Hypoglycemia	High SOE favoring long- acting insulin analogues	High SOE favoring premixed human insulin	Low SOE; unable to make a conclusion	High SOE favoring noninsulin antidiabetic agents
Weight	Moderate SOE favoring long-acting insulin analogues	Moderate SOE suggesting similar effectiveness	Low SOE; unable to make a conclusion	Moderate SOE favoring noninsulin antidiabetic agents
All-cause mortality, CVD mortality and morbidity	Low SOE; unable to make a conclusion

Definitions for strength of evidence: High = further research is very unlikely to change our confidence in the estimates; Moderate = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low = further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

CVD = cardiovascular disease; NA = not applicable; SOE = strength of evidence